{"id":474072,"date":"2020-03-16T11:36:01","date_gmt":"2020-03-16T11:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474072"},"modified":"2020-03-16T11:36:01","modified_gmt":"2020-03-16T11:36:01","slug":"uveitis-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/uveitis-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_474072.html","title":{"rendered":"Uveitis Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Uveitis<\/a><\/p>\n
\n
“Uveitis- Market Insight, Epidemiology and Market Forecast -2030”<\/div>\n<\/div>\n<\/div>\n

Albany, US –<\/strong> DelveInsight has launched a new report on Uveitis Market Insights, Epidemiology and Market Forecast-2030<\/a><\/p>\n

DelveInsight’s “Uveitis – Market Insights, Epidemiology, and Market Forecast-2030” <\/strong>report delivers an in-depth understanding of the Uveitis , historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. The therapeutic market of Uveitis in the seven major markets was USD 1027.0 million in 2017.<\/li>\n
  2. The total prevalent cases of Uveitis in the US were observed to be 357,791 in 2017.<\/li>\n
  3. In 2017, it was found that there were 26,550 diagnosed cases of infectious uveitis in the<\/li>\n<\/ol>\n

     United States.<\/p>\n

      \n
    1. In 2017, it was found that there were 277,573 diagnosed cases of non-infectious uveitis in the United States.<\/li>\n<\/ol>\n

       <\/p>\n

      Key benefits of the Report<\/strong><\/p>\n

      1. Uveitis market report covers a descriptive overview and comprehensive insight of the Uveitis epidemiology and Uveitis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

      2. Uveitis market report provides insights on the current and emerging therapies. <\/p>\n

      3. Uveitis market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

      4. Uveitis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Uveitis market.<\/p>\n

      Request for Sample Pages: <\/strong> https:\/\/www.delveinsight.com\/sample-request\/uveitis-market<\/a><\/p>\n

       “According to DelveInsight, the majority of cases of Uveitis are female as compared to male. There were total 154,190 female and 149,932 male cases of Uveitis in 2017 in the United States.”<\/em><\/strong><\/p>\n

       <\/p>\n

      \"\"<\/em><\/strong><\/p>\n

       <\/p>\n

      Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. It is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.<\/p>\n

      Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (Panuveitis) implies inflammation of the entire uveals tract.<\/p>\n

      Symptoms of acute forms of uveitis include ocular pain, photophobia, lacrimation, and redness. Uveitis is most often idiopathic but has been associated with traumatic, inflammatory, and infectious processes.<\/p>\n

                      <\/em><\/strong><\/p>\n

      Some of the key companies working on Uveitis are:<\/strong><\/p>\n